Abeona Therapeutics Inc. (ABEO)

Market Cap	311.48M -5.2%
Revenue (ttm)	14.54M
Net Income	66.14M
EPS	0.91
Shares Out	57.00M
PE Ratio	5.98
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	881,773
Open	5.78
Previous Close	5.82
Day's Range	5.42 - 5.83
52-Week Range	4.00 - 7.54
Beta	1.35
Analysts	Strong Buy
Price Target	19.71 (+260.66%)
Earnings Date	May 13, 2026

About ABEO

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 19, 1980
• Employees: 226
• Stock Exchange: NASDAQ
• Ticker Symbol: ABEO
• Website: https://www.abeonatherapeutics.com

Analyst Summary

According to 6 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price target is $19.71, which is an increase of 260.66% from the latest price.

Price Target

$19.71

(260.66% upside)

Analyst Consensus: Strong Buy